Liubov Kriel

Liubov Kriel serves as a secondary procurement professional within the Department of Health and Human Services, supporting the agency’s mission to advance public health through scientific innovation and laboratory infrastructure. While not the primary contracting officer, she plays a critical role in facilitating complex acquisitions related to biomedical research, diagnostic technologies, and technical services. Her work centers on supporting high-priority scientific initiatives by ensuring timely and compliant procurement of specialized equipment, analytical instruments, and professional consulting services essential to federal health research operations. Kriel collaborates closely with a core group of established contractors including America’s Health Insurance Plans, Inc., Leidos Biomedical Research Inc., General Dynamics Information Technology, Inc., and Advanced Technology International. These partnerships reflect a pattern of engagement with large, technically capable firms experienced in supporting federal biomedical R&D, laboratory automation, and health data systems. Her procurement activities consistently involve technical service contracts requiring deep domain expertise in biotechnology, clinical diagnostics, and health infrastructure support. Her contracting portfolio exhibits a strong preference for open competition, with over 90% of acquisitions conducted without set-asides, indicating a focus on technical capability and mission-critical delivery over socioeconomic preferences. When small business opportunities are pursued, they are primarily structured as total small business set-asides under FAR 19.5, reflecting a measured but deliberate commitment to expanding vendor diversity within high-complexity technical domains. Her primary procurement focus lies in NAICS 334516 (analytical laboratory instrument manufacturing) and 541990 (professional scientific services), underscoring expertise in acquiring advanced diagnostic equipment, in-vitro diagnostic substances, and specialized technical consulting. This aligns with HHS’s strategic emphasis on molecular diagnostics, biotechnology R&D, and operational readiness of public health laboratories, positioning her at the intersection of scientific advancement and federal acquisition excellence.